GEFITINIB ALVOGEN 250mg tablets medication leaflet

L01EB01 gefitinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Gefitinib is a medication used for the treatment of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor (EGFR) mutations. It is a tyrosine kinase inhibitor.

This medication works by blocking signals that promote the growth and division of cancer cells. It is taken orally, usually once daily, as directed by a doctor.

Common side effects include diarrhea, skin rash, nausea, and fatigue. In rare cases, severe reactions such as interstitial lung disease may occur.

It is important to follow your doctor's instructions closely and report any side effects or unusual symptoms. Regular monitoring is necessary to assess treatment effectiveness.

General data about GEFITINIB ALVOGEN 250mg

Substance: gefitinib

Date of last drug list: 01-06-2025

Commercial code: W65598001

Concentration: 250mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Price: 4802.30 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA

Holder: ALVOGEN MALTA OPERATIONS (ROW) LTD. - MALTA

Number: 11302/2018/01

Shelf life: 2 years

Other substances similar to gefitinib

Compensation lists for GEFITINIB ALVOGEN 250mg ALVOGEN

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

4802.30 RON

2878.56 RON

1923.74 RON